GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aeolus Pharmaceuticals Inc (OTCPK:AOLS) » Definitions » Shares Outstanding (EOP)

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Shares Outstanding (EOP) : 152.09 Mil (As of Jun. 2017)


View and export this data going back to 1996. Start your Free Trial

What is Aeolus Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aeolus Pharmaceuticals's shares outstanding for the quarter that ended in Jun. 2017 was 152.09 Mil.

Aeolus Pharmaceuticals's quarterly shares outstanding stayed the same from Mar. 2017 (152.09 Mil) to Jun. 2017 (152.09 Mil).

Aeolus Pharmaceuticals's annual shares outstanding increased from Sep. 2015 (135.93 Mil) to Sep. 2016 (152.09 Mil). It means Aeolus Pharmaceuticals issued new shares from Sep. 2015 to Sep. 2016 .


Aeolus Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Aeolus Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aeolus Pharmaceuticals Shares Outstanding (EOP) Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.73 134.55 135.85 135.93 152.09

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.09 152.09 152.09 152.09 152.09

Competitive Comparison of Aeolus Pharmaceuticals's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Shares Outstanding (EOP) falls into.



Aeolus Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Aeolus Pharmaceuticals  (OTCPK:AOLS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Aeolus Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Aeolus Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Executives
John L Mcmanus officer: President and CEO C/O AEOLUS PHARMACEUTICALS, INC., 26361 CROWN VALLEY PARKWAY, SUITE 150, MISSION VIEJO CA 92691
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Amit Kumar director C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Joseph J Krivulka director C/O DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Michael E Lewis director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Peter David Suzdak director 1204 MEADOWLARK DRIVE, TOWSON MD 21286
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Mark Lappe 10 percent owner 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Bvf Investments Llc 10 percent owner, other: Indirect Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jon Faiz Kayyem 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Headlines

From GuruFocus